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Abstract: Shielding agents are commonly used to shield polyelectrolyte complexes, e.g., polyplexes, from
agglomeration and precipitation in complex media like blood, and thus enhance their in vivo circulation
times. Since up to now primarily poly(ethylene glycol) (PEG) has been investigated to shield non-viral
carriers for systemic delivery, we report on the use of polysarcosine (pSar) as a potential alternative for
steric stabilization. A redox-sensitive, cationizable lipo-oligomer structure (containing two cholanic acids
attached via a bioreducible disulfide linker to an oligoaminoamide backbone in T-shape configuration)
was equipped with azide-functionality by solid phase supported synthesis. After mixing with small
interfering RNA (siRNA), lipopolyplexes formed spontaneously and were further surface-functionalized
with polysarcosines. Polysarcosine was synthesized by living controlled ring-opening polymerization
using an azide-reactive dibenzo-aza-cyclooctyne-amine as an initiator. The shielding ability of the
resulting formulations was investigated with biophysical assays and by near-infrared fluorescence
bioimaging in mice. The modification of ~100 nm lipopolyplexes was only slightly increased upon
functionalization. Cellular uptake into cells was strongly reduced by the pSar shielding. Moreover,
polysarcosine-shielded polyplexes showed enhanced blood circulation times in bioimaging studies
compared to unshielded polyplexes and similar to PEG-shielded polyplexes. Therefore, polysarcosine is
a promising alternative for the shielding of non-viral, lipo-cationic polyplexes.
Keywords: shielding agent; polysarcosine; biodistribution; click-chemistry; lipopolyplex; nucleic
acid carrier
1. Introduction
Therapeutic nucleic acids are powerful tools, which can be used to specifically control gene
expression inside cells [1–5]. For several diseases, including severe metastatic tumors, systemic delivery
is required to achieve therapeutic effects. Naked oligonucleotides have limited stability in biological
fluids because they are actively targeted and consequently, degraded by nucleases. Although this
issue might be addressed by chemical modifications [6,7], the renal clearance of small oligonucleotides
or siRNA usually occurs within a few minutes, which limits the time to reach their desired site of
action [8,9]. Lipopolymer micelles, liposome-based formulations, and polymer-based complexes
increase the size usually beyond the renal cut-off and thus enhance circulation times, whenever
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a stealth-like corona protects the systems from unspecific aggregation [6,10–21]. Various cationic lipids,
polycations and combinations with helper lipids [4,14,16,17,22–24] were used to form lipoplexes or
lipid nanoparticles (LNPs) [1,11,25–30]. Precise editing of the compounds’ chemical structure enables
the fine-tuning of a carrier’s stability and size, but also other properties, which are important for the
delivery process like cellular uptake, endosomal escape ability, and cell tolerability [31–34].
Solid phase-supported synthesis (SPS) is a very convenient and precise way to optimize a delivery
system in a step-wise manner [18,35]. Recently, we developed our own customized amino acids, such as
succinoyl tetraethylene pentamine (Stp), which contains of short defined repeats of the ethylenediamine
motif prepared in boc/fmoc protected form. With artificial building blocks, natural α-amino acids
and fatty acids, we sequentially synthesized monodisperse cationic oligomers via SPS, which are
highly adaptable to different demands in the field of gene delivery [8,12,18,31–33,36–39]. By precise
incorporation of a bioreducible cleavage site between the cationic and a lipophilic block, for instance,
it was possible to destabilize polyplexes only after reaching the cytoplasm of the cell [39]. Thereby the
carrier system remained stable in serum and transfection efficiency as well as cell viability could be
increased in certain cell lines.
Besides size and stability, the surface character of a nanoparticle is of utmost importance for its
systemic delivery. Shielding agents attached to the surface prevent interactions with neighboring
particles and/or blood components, which usually leads to extended circulation in the body’s
bloodstream [40–42]. Already in 1990, it could be demonstrated that polyethylene glycol (PEG) could
extend the blood circulation half-life of systemically injected liposomes from <30 min to several hours [40].
Its hydrophilic character enables PEG to generate a hydrated shell covering the nanoparticles and
thereby sterically reduce unwanted interactions with biomolecules or other poly- or lipoplexes [43].
PEG is the most prominent shielding agent and has often been used to shield cationic polyplexes
in numerous applications [44–49]. A major drawback, however, is that more and more researchers
in academia or industry observe immune responses towards PEGylated nanoparticles [43,50–55].
For this reason, several new alternatives were evaluated for shielding, such as natural proteins [56],
oligosaccharides [57,58], poly(N-(2-hydroxypropyl)methacrylamide) (pHPMA) [58–60], hydroxyethyl
starch (HES) [61] or polypeptides (poly(glutamic acid) [62], poly(hydroxyethyl-L-asparagine) [63],
poly(hydroxyethyl-L-glutamine) [63], proline-alanine-serine motif (PAS) [64,65]). Nevertheless, according
to the Whitesides’ rules for protein resistant surfaces an ideal alternative to PEG should mimic its
chemical properties, being a hydrophilic, non-charged polymer and a weak hydrogen acceptor without
donor properties, which is not the case for all above-mentioned polymers. In contrast, polysarcosine
fulfills all the described criteria and has already demonstrated protein resistant properties on various
surfaces [66–68]. In addition, it can be also synthesized by living controlled ring-opening polymerization
of the corresponding N-carboxyanhydrides (NCAs) [69,70]. However, in vivo data on polysarcosine is
rarely reported in literature [71]. In contrast to polypeptides, the side chain of polypeptoids is situated
at the nitrogen rather than the α-carbon, in the case of pSar the nitrogen is methylated. As a result,
polysarcosine adopts a random coil conformation in aqueous solution and possesses a comparable
second virial coefficient and molecular weight dependency like PEG [72]. All these properties mediate
high resistance against protein adsorption [73] and make it in theory an ideal material for shielding
electrostatic complexes in vivo [74]. Importantly, it has been reported that polysarcosine has so far
demonstrated neglectable complement activation or immunogenicity in mouse, rat and rabbit animal
models [75,76]. pSar-shielded polyplexes, micelles, colloids and nanohydrogels demonstrated the
absence of aggregation in human serum [77–80].
In the current work, we have incorporated azide domains into a previously described
redox-sensitive T-shaped bis-(cholanic acid amido) oligoaminoamide siRNA carrier system [39] and
used strain-promoted azide-alkyne cycloaddition (SPAAC) reaction to equip the lipopolyplexes’ surface
with ~8 kDa polysarcosine (DP = 119) chains. We report on the ability of polysarcosine to shield siRNA
lipoplexes and analyzed the in vivo stability and biodistribution after intravenous administration into
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mice. In a second approach, we modified the system with a folate ligand to target the folate receptor
overexpressed on certain cancer cells [81–86].
2. Materials and Methods
2.1. Materials
Protected Fmoc-α-amino acids, N,N-dimethylformamide (DMF), N,N-diisopropylethylamine
(DIPEA), trifluoroacetic acid (TFA) and 2-chlorotrityl chloride resin for solid-phase syntheses
were purchased from Iris Biotech (Marktredewitz, Germany). 1-hydroxybenzotriazole (HOBt),
triisopropylsilane (TIS), 5β cholanic acid. Dimethylformamide (DMF, 99.8% Extra) for
Dibenzoazacyclooctyneamine polysarcosine (DBCO-pSar) syntheses was purchased from Acros
Organics (Nidderau, Germany), further dried over CaH2 and fractionally distilled in vacuo.
Tetrahydrofuran (THF) and folic acid (FolA, 96–102% pure) was purchased from Acros Organics.
Triethylamine (TEA) and N,N-diisopropylethylamine (DIPEA) were dried over NaOH and fractionally
distilled in vacuo. (Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluoro-phosphate (PyBOP),
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorphosphate (HBTU) and microreactors
were purchased from MultiSynTech (Witten, Germany). Cell culture media, antibiotics and fetal
bovine serum (FBS) were obtained from Invitrogen (Karlsruhe, Germany), HEPES from Biomol
GmbH (Hamburg, Germany), agarose (NEEO Ultra-quality) from Carl Roth GmbH (Karlsruhe,
Germany), glucose from Merck (Darmstadt, Germany), and GelRed™ from VWR (Darmstadt,
Germany). D-Luciferin sodium salt and cell culture 5 × lysis buffer were purchased from
Promega (Mannheim, Germany). Ready-to-use siRNA duplexes were purchased from Axolabs
GmbH (Kulmbach, Germany): eGFP-targeting siRNA (siGFP) (sense: 5′-AuAucAuGGccGAcAA
GcAdTsdT-3′; antisense: 5′-UGCUUGUCGGCcAUGAuAUdTsdT-3′) for silencing of eGFPLuc;
control siRNA (siCtrl) (sense: 5′-AuGuAuuGGccuGuAuuAGdTsdT-3′; antisense: 5′-CuAAuAc
AGGCcAAuAcAUdTsdT-3′); Cy5-labled siRNA (Cy5-siAHA1) (sense: 5′-(Cy5)(NHC6)GGAu
GAAGuGGAGAuuAGudTsdT-3′; antisense: 5′-ACuAAUCUCcACUUcA- UCCdTsdT-3′); Cy7-labled
siRNA (Cy7-siAHA1) (sense: 5′-(Cy7)(NHC6)GGAuGAAGuGGAG- AuuAGudTsdT-3′; antisense:
5′-ACuAAUCUCcACUUcAUCCdTsdT-3′) small letters: 2’methoxylated; s: phosphorothioate.
All other chemicals were obtained from Sigma (Munich, Germany), Merck, Iris Biotech (Marktredwitz,
Germany) or AppliChem (Darmstadt, Germany), Acros Organics, Fluka (Munich, Germany) or Alfa
Aesar (Karlsruhe, Germany).
2.2. Synthesis of Oligomers and DBCO Shielding Agents
2.2.1. Synthesis of Oligomers
See Supporting Information for detailed descriptions of the syntheses of oligomers.
2.2.2. Synthesis of Sarcosine-N-Carboxyanhydride
The synthesis was performed as described in Klinker et al. [71] Sarcosine (15.16 g, 170.2 mmol,
1 eq) was weighed into a pre-dried three-necked flask and dried under vacuum for one hour. Absolute
(abs) tetrahydro furane (THF) (300 mL) was added under a steady nitrogen flow. Two gas washing
bottles with aqueous sodium hydroxide solution were connected to the apparatus. Diphosgene
(16.26 mL, 134 mmol, 0.8 eq) was added dropwise via syringe. The colorless suspension was heated
to 70 ◦C resulting in a clear solution after three hours of stirring. The solvent was evaporated under
reduced pressure resulting in a brown oil as crude reaction product. The obtained oil was heated to
50 ◦C and dried under reduced pressure yielding an amorphous solid. The solid was redissolved
in 60 mL THF and precipitated by adding 300 mL abs n-hexane. The precipitate was filtered off
under nitrogen-atmosphere and dried with a stream of dry N2 for 60–90 min to remove remaining
traces of solvents. The next day, the solid was dried in high vacuum for 2 h in the sublimation
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apparatus followed by sublimation at 80–85 ◦C and <1 × 10−2 mbar. The product was collected from
the sublimation apparatus in a glove box the same day. Colorless crystals were obtained (50–67%).
mp = 104.3 ◦C; 1H-NMR (300 MHz, CDCl3) δ [ppm] = 2.86 (s, 3H, N−CH3), 4.22 (s, 2H, N−CH2CO).
2.2.3. Synthesis of DBCO-pSar
DBCO-pSar was synthesized using ring-opening polymerization of SarNCA as described in
Klinker et al. [71] In a typical experiment, SarNCA (461.8 mg, 4.012 mmol) were transferred under N2
counter flow into a pre-dried Schlenk-tube, equipped with a stir bar and dried again in vacuum for
30 min. The NCA was dissolved in dry DMF (3.5 mL). A stock solution of DBCO-amine (0.074 mmol,
1/110 eq, M/I = 110) in DMF (2 mL) was freshly prepared and 1 mL of this stock solution was added
to the monomer solution with syringe. The solution was stirred at a temperature of 40 ◦C and kept
at a constant pressure of 1.25 bar of dry N2 via the Schlenk-line to prevent impurities from entering
into the reaction vessel while allowing CO2 to escape. Completion of the reaction was confirmed
by infrared spectroscopy (disappearance of the NCA peaks (1853 and 1786 cm−1)). Directly after
completion, the polymer was precipitated in ice-cold diethyl ether and centrifuged (4500 rpm at 4 ◦C
for 15 min). After discarding the liquid fraction, new diethyl ether was added and the polymer was
resuspended via sonication. Again, the suspension was centrifuged and the procedure was repeated.
The polymer was subsequently dissolved in water and lyophilized to obtain a fluffy powder (279.7 mg,
98%). 1H-NMR: (400 MHz, DMSO−d6): δ [ppm] = 0.88–0.79 (m, ini, 9H, –C(CH3)3), 2.58–3.11 (br, 3nH,
N–CH3), 3.73–4.57 (br, 2nH, –CO–CH2–N), = 7.86–7.10 (m, 8H, benzylic protons).
2.2.4. Synthesis of DBCO-pSar-Ac
DBCO-pSar119 (Mn = 8735 g mol−1) (36 mg, 0.004 mmol), acetic anhydride (4.2 mg, 3.9 µL, 0.04
mmol), and triethylamine (10.7 mg, 14.6 µL, 0.08 mmol) were dissolved in absolute DMF (1 mL) and
stirred at 25 ◦C for 24 h under an argon atmosphere. Subsequently, the polymer was precipitated in
diethyl ether, extensively dialyzed against water (MWCO = 3500 g mol−1), and lyophilized. Yield after
dialysis: 25 mg (69%).
2.2.5. Synthesis of DBCO-pSar-FolA
DBCO-pSar110 (Mn = 8095 g mol−1) (55.8 mg, 0.007 mmol) was separately dissolved in absolute
5mL dimethylsulfoxid (DMSO). Folic acid (30.4 mg, 0.068 mmol), HBTU (26.1 mg, 0.068 mmol),
and HOBt (9.31 mg, 0.068 mmol) were dissolved in 5mL DMSO and cooled to 0 ◦C. DIPEA (17.8 mg,
24.0 µL, 0.138 mmol) was added and the mixture was left to react for 30 min at 0 ◦C. The in situ
formed activated ester was added to the predissolved polymer and the reaction mixture was stirred at
25 ◦C for 24 h under an argon atmosphere. The crude reaction product was purified by size exclusion
chromatography in DMSO using a Sephadex LH-20-packed column. The purified conjugate was
lyophilized from water. Yield after SEC: 31 mg (55%).
2.2.6. Gel Permeation Chromatography
Polymer molecular weight and dispersity index were determined using gel permeation
chromatography (GPC). GPC in hexafluoro-2-propanol (HFIP) was performed with 3 g L−1 potassium
trifluoroacetate (KTFA) at a temperature of 40 ◦C. The columns were packed with modified silica (PFG
columns, particle size: 7 µm; porosity: 100 and 1000 Å). A UV/vis detector (UV-2075 Plus, JASCO,
Groß-Umstadt, Germany, λ = 230 nm; λ = 330 nm for folic acid detection) and a refractive index detector
(G 1362A RID, Jasco) were used to detect the polymer. Molecular weights were calculated by using
calibration performed with PMMA standards (Polymer Standards Services GmbH, Mainz, Germany)
Toluene was used as the internal standard.
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2.2.7. UV-Vis Spectroscopy
UV-vis absorbance spectra were recorded using a V-630 spectrophotometer (Jasco) with water
being the solvent.
2.3. Formation of siRNA Polyplexes
siRNA was diluted with 20 mM HEPES buffered 5% glucose pH 7.4 (HBG) to a concentration
of 50 ng/µL for in vitro experiments and 500 ng/µL for in vivo experiments. According to the
indicated nitrogen/phosphate (N/P) ratio, the oligomer solution was prepared in a separate tube.
Only protonatable nitrogens of an oligomer were considered in the N/P calculation. The same volume
of siRNA solution was added to the oligomer. The mixture was rapidly pipetted at least five times and
incubated for 40 min at RT yielding a polyplex solution with 25 or 250 ng of siRNA/µL respectively.
2.4. Functionalization of Polyplexes with DBCO Reagents
For functionalization of siRNA polyplexes with DBCO click agents, solutions with DBCO reagents
were prepared in 1⁄4 of the volume of the previously prepared polyplex solutions. The concentration of
the solution was calculated according to the indicated equivalents (eq) used. Equivalents represent the
molar ratio of shielding agent to cationic oligomer in the polyplex solution. The reaction time was 16 h
for biophysical and in vitro assays and 4 h for in vivo experiment respectively.
2.5. siRNA Binding Assays
siRNA binding assays were performed analogously as described in Klein et al. [86]. A 1% agarose
gel was prepared by dissolving agarose in TBE buffer (10.8 g of Trizma base, 5.5 g of boric acid, 0.75 g
of disodium EDTA, and 1 L of water) and subsequent boiling. After cooling down to about 50 ◦C,
GelRedTM was added. Formulations were prepared with 500 ng of siRNA per sample. Samples were
placed into the pockets after 4 µL of loading buffer (prepared from 6 mL of glycerine, 1.2 mL of 0.5 M
EDTA, 2.8 mL of H2O, 0.02 g of bromophenol blue) was added. Electrophoresis was performed at 70 V
for 60 min.
2.6. Particle Size and Zeta Potential Measurements
Polyplexes were formed using 2 µg siRNA in a total volume of 80 µL. Dynamic light scattering
(DLS) measurements of polyplex solutions were performed in a folded capillary cell (DTS 1070).
A Zetasizer Nano ZS with backscatter detection (Malvern Instruments, Worcestershire, UK) was used
for the measurements. For size measurements, the equilibration time was 0 min, the temperature
was set to 25 ◦C and an automatic adjustment of the attenuator was used. The refractive index of
the solvent was set to 1.330 and the viscosity was set to 0.8872 mPa·s. Each sample was measured
three times. For detection of the zeta potential, the sample was diluted to 800 µL volume with 10 mM
NaCl solution. Measurements with at least 6 runs were performed. Zeta potentials were calculated
using the Smoluchowski equation. 10 to 15 sub runs each lasting 10 s (n = 3) were measured.
2.7. Cell Culture
The mouse neuroblastoma cells (Neuro2a) were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) low glucose medium (Sigma). As FR-expressing cell lines, human cervix carcinoma cells
(KB cells), and human cervix carcinoma cells transfected stably with the eGFPLuc (enhanced green
fluorescent protein/luciferase) gene (KB/eGFPLuc cells) were cultured in folate-free Roswell Park
Memorial Institute medium (RPMI) 1640 (Invitrogen). All media were supplemented with 10% FBS,
100 U/mL penicillin, and 100 µg/mL streptomycin. The cells were cultured in ventilated flasks in the
cell incubator at 37 ◦C and 5% CO2 in a humidified atmosphere. After a confluency of 80–90% was
reached, cells were harvested.
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2.8. Cell Association and Internalization of siRNA Polyplexes Measured with Flow Cytometry
For untargeted polyplexes, Neuro2a cells were seeded in 24-well plates with 5 × 104 cells/well
24 h prior the experiment, and fresh growth medium was provided immediately before the experiment.
Polyplexes containing 1.5 µg of siRNA (20% Cy5-labeled siRNA + 80% unlabeled siRNA) were pipetted
into each well and incubated for four hours at 37 ◦C in 5% CO2. Polyplexes non-specifically associated
to the cell surface were then removed by incubating cells with 500 I.U. heparin. For folate-targeted
polyplexes, KB cells were seeded in 24-well plates with 5 × 104 cells perwell at 24 h before the
experiment, and fresh growth medium was provided before the experiment. Polyplexes containing
1.5 µg of siRNA (20% Cy5-labeled siRNA + 80% unlabeled siRNA) were pipetted into each well,
incubated 30 min on ice for cell association or 45 min at 37 ◦C in 5% CO2 in case of cellular internalization.
Cells were then washed with PBS to remove free polyplexes. In case of testing the cellular internalization,
polyplexes non-specifically associated to the cell surface were then removed by incubation with 500 I.U.
heparin. Next, cells were collected and resuspended in PBS buffer containing 10% of FBS. All samples
were analyzed by flow cytometry with CyanTM ADP (Dako, Hamburg, Germany) using an excitation
wavelength of 635 nm, and detecting the emission at 665 nm. Dead cells were differentiated by
fluorescence of DAPI and removed by gating in order to only analyze cellular uptake of polyplexes in
living cells. Flow cytometry data were analyzed using FlowJo 7.6.5 flow cytometric analysis software
by FlowJo, LLC (Ashland, OR, USA).
2.9. Confocal Laser Scanning Microscopy (CLSM)
Neuro2a cells were seeded at a density of 3 × 104 cells/well in 300 µL of growth medium into an
8-well Lab-Tek chamber slide (Nunc, Schwerte, Germany) 24 h prior to treatment. Polyplexes were
formed as described using a 1.5 µg of a mixture of 80% of siCtrl and 20% Cy5-labeled siRNA and
oligomer at N/P 12 in 60 µL of HBG followed by the indicated agent in 20 µL. Cells were incubated
with 220 µL of fresh growth medium and the polyplex solution was applied. For the uptake study,
the incubation with polyplexes was at 37 ◦C for 4 h. The growth medium was removed, cells were
washed twice with 300 µL of PBS and fixed with 4% PFA solution for 30 min at RT. Cell nuclei were
stained with DAPI. For image acquisition, a TCS SP8 confocal microscope (Leica, Mannheim, Germany)
was used.
2.10. Mouse Tumor Model
Female six- to seven-week-old nude mice, Rj: NMRI-nu (nu/nu) (Janvier, Le Genest-Saint-Isle,
France), were housed in isolated ventilated cages under pathogen-free condition with a 12 h light/dark
interval and were acclimated for at least seven days prior to experiments. Water and food were
provided ad libitum. Injection of animals was performed subcutaneously with 5 × 106 Neuro2a cells.
The tumor volume was measured by caliper and calculated as [0.5 × (longest diameter) × (shortest
diameter)2] and the body weight was recorded. All animal experiments were performed according
to the terms stated in the proposal “Entwicklung von Sequenz-definierten Oligomeren als Träger für
die zielgerichtete Einbringung neuer molekularer Therapeutika in Tumore“ that was approved by
the local animal ethics committee and the government of Oberbayern at the 26 May 2014. All animal
studies were performed according to guidelines of the German Animal Welfare Act.
2.11. Biodistribution Study
A mixture of 50% unlabeled control siRNA (siCtrl) and 50% of Cy7-labeled siRNA (Cy7-siAHA1)
in HBG was used for all near infrared (NIR) in vivo imaging experiments. Tumors of mice were allowed
to grow until reaching a size of 500–1000 mm3. The mice (n = 2/per group) were anesthetized with 3%
isoflurane in oxygen. siRNA polyplexes containing 50 µg siRNA (50% Cy7-labeled—N/P 10) in 250
µL (prepared from 100 µL of siRNA solution, 100 µL of oligomer solution and 50 µL of agent solution
or buffer) or HBG as negative control were injected intravenously (i.v.), and fluorescence intensity
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was measured with a CCD camera at different time points. For evaluation of images, the intensity of
fluorescence signals was analyzed after color bar scales were equalized using the IVIS Lumina system
and the Living Image software 3.2 (Caliper Life Sciences, Hopkinton, MA, USA).
3. Results and Discussion
3.1. Design and Synthesis of Lipo-Oligomers for Click Chemistry
Previously, we have established a novel class of redox-sensitive lipo-oligomers that were prepared
by solid-phase supported synthesis (SPSS) serving as carriers for siRNA delivery [39]. Beside all beneficial
effects of lipid-based delivery systems, such as endosomal escape capability and enhanced nanoparticle
stability, the in vivo distribution is often limited to certain tissues, primarily liver, lung and spleen [87–89].
In previous work, it has been shown that T-shape oligomers similar to the ones, which were synthesized
in this approach demonstrate strongest retention in liver tissue [89,90]. This observation might be
related to a high stickiness of cationic particles, but it is also possible that certain serum proteins, which
incorporate onto nanoparticle surfaces may impair tissue specificity [88,91–93]. An efficient shielding
should reduce both types of interactions and should enable a better distribution in the body. Therefore,
one of the top candidates from redox-sensitive lipo-oligomers, T-shape structure T-0N3 (published as ID
992 in [39]) was chosen and extended by click-reactive azide functionality. After the formation of siRNA
lipopolyplexes, the surface was further modified with the shielding agents.
T-0N3 was chosen as a lead structure and starting point for further modifications, because it
forms stable siRNA polyplexes smaller than 200 nm in hydrodynamic diameter, which show high
transfection efficiency in mouse neuroblastoma (Neuro2a) cells. This structure combines natural amino
acids and artificial building blocks (Figure 1, top). It consists of four repeats of the artificial, cationic
polyamino acid succinoyltetraethylenepentamine (Stp) used for complexation of nucleic acid and for
endosomal buffering. Two trimeric tyrosine units flanking the cationic domain are able to stabilize
the polyplex due to their hydrophobicity and pi–pi stacking ability. In between the cationic Stp units,
two hydrophobic cholanic acids branch off the backbone (T-shape).
This hydrophobic domain mediates efficient lipopolyplex stabilization. The lipid and cationic
domains are connected with a bioreducible linking unit (ssbb) [39]. In this approach, the azide function
was incorporated into the lipo-oligomer during standard Fmoc solid phase-supported synthesis via
an azidolysine residue at the N- and/or C-terminus of the backbone (structures T-1N3 with one azide
and T-2N3 with two azides, Figure 1, top). Consequently, the structure can be subsequently further
modified with an alkyne-bearing functional group via click chemistry.
3.2. Synthesis of DBCO-Modified Polysarcosine
Polysarcosine is a hydrophilic, nonionic peptoidic structure with exclusively weak hydrogen bond
acceptor properties. As shown empirically by Whitesides and co-workers for protein-resistant surfaces,
these properties are essential to achieve “stealth”-like properties in a material [71,74]. Polysarcosine
can be functionalized at its N-terminal (via post-polymerization modification) and C-terminal
(via functional initiators) end. It is conveniently synthesized by controlled living ring-opening
polymerization of α-amino acid N-carboxyanhydrides (NCA) with low dispersity index (ÐGPC ≤ 1.1;
see Table S1) [71]. Initiating the reaction with dibenzoazacyclooctyneamine (DBCO-amine) leads
to a C-terminal DBCO end group (Figure S1A) [94]. To ensure end group accessibility and steric
stabilization at once, we aimed for a degree of polymerization of around 115, which correlates with
the PEG5k used as reference material. Therefore, a theoretical degree of polymerization of 115 was
set by the monomer to initiator ratio. The polymerization was carried out under the conditions
recently reported by Klinker et al. [95], NMR end group and SEC analysis (using pSar standards as
described by Weber et al. [72]) revealed a number average degree of polymerization (DP) of 119 and
a number average molecular weight of 8735 g mol−1 (Table S1), which is within the experimental
error. The experimentally determined molecular weight is perfectly in line with the calculated one.
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The synthesized polymer displays a symmetrical SEC elugram indicating a Poisson-like molecular
weight distribution, as expected for the amine initiated N-substituted glycine N-carboxyanhydride
(NNCA) polymerization. The terminal DBCO can be clearly detected in the 1H-NMR spectra and thus
can be employed for the strain promoted azide-alkyne cycloadditon (SPAAC) with azides. For SPAAC
no catalyst is needed, no toxic by-products are generated, and no side reactions with other functional
domains of the oligomer can occur [96]. Mixing azide-modified cationic lipo-oligomers with siRNA
leads to spontaneous assembly of lipopolyplexes. Due to oligomer excess, several azide functionalities
are accessible on the polyplex surface and can serve as attachment points for functionalization with
DBCO-modified pSar. The N-terminal free amine group can further be modified with carboxylic
acid-bearing molecules to introduce a second functionality, e.g., targeting ligands such as folic acid or
alternatively may be capped by acetylation to remove the terminal amine, which is positively charged
in aqueous solution of neutral pH. All synthesized agents are presented in Figure 1.
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succinoyl-tetraethylene-pentamine, ssbb: succinoyl-cystamine, CholA: 5β-Cholanic acid, Y: tyrosine, 
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Figure 1. Overview of chemical compounds. Table, top: structural illustration of sequence-defined
oligomers with T-shape topology; T-0N3 (ID: 992 published [39]), T-1N3 (ID: 1073) and T-2N3
(ID: 1086) with no, one or two terminal azidolysines K(N3). Further units of the oligomers: Stp:
succinoyl-t traethylene-pentamine, ss b: su cinoyl- t ine, CholA: 5β-Cholanic a id, Y: tyrosine,
K: lysine, G: glycine. The broken lines represent a i ages, the triangle (N) is the starting point
of the synthesis. IDs are unique database ide tificati numbers. Table, bott m: chemical structure
of the shielding agents DBCO-pSar119, DBCO-pSar119-Ac and DBCO-pSar110-FolA. Scheme of the
formulation of a shielded polyplex.
3.3. Polyplex Formation and pSar-Shielding
For polyplex formation, the structures T-1N3 and T-2N3 were incubated with siRNA for 40 min at
a final concentration of 25 ng siRNA/µL. The nucleic acid binding ability was evaluated by measuring
the electrophoretic mobility of incorporated siRNA within an agarose gel. Different N/P values depict
the ratio of protonatable amines (N) within an oligomer to the phosphates (P) of the siRNA. Like its
azide-free analogue T-0N3 [39], the new azide-containing oligomers showed complete retention of the
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nucleic acid in the pockets of the gel at an N/P ratio of 12 (Figure S2). The binding ability observed for
structures containing one or two azides did not differ.
Next, the heterotelechelic polysarcosine with DBCO-end group (DBCO-pSar119; Figure 1, bottom)
was used to react with the azides on the preformed polyplexes (N/P ratio 12) to introduce a shielding
layer. The SPAAC was allowed to proceed until full conversion for 16 h (see scheme in Figure 1, bottom).
Afterwards, the influence of the pSar shielding agent on electrophoretic mobility was evaluated
with respect to the number of azide functions incorporated into the polyplex-forming core structures
(N3 = 0, 1, 2). The amount of DBCO-pSar119 added to the polyplexes was kept constant (Figure 2A).
In this experiment, only the azide-bearing polyplexes migrated in the agarose gel towards the
cathode, whereas the azide-free polyplex remained in the loading pocket. This demonstrates that
a covalent bond connecting the shielding agent to the nanoparticle is crucial to provide this migratory
effect. The migration of the integrated nucleic acid against its own negative charge shows that it is
fully shielded against the force of the electric field. With increasing equivalents of DBCO-pSar119,
stronger migration could be observed. This effect can be explained by the degree of polyplex surface
modification (Figure 2B). For the oligomer with only one azide functionality (T-1N3), maximum
migration was achieved with equimolar amounts of DBCO click agent (1 eq/oligomer). More
DBCO-pSar119 (2 eq) did not increase the effect. T-2N3 siRNA polyplexes with two azide functionalities
within the carrier also revealed the maximum migration for equimolar ratios of azide to DBCO (2 eq
DBCO-pSar119). These findings are in line with covalent modification with PEG5k [86].
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Figure 2. Electrophoretic mobility of siRNA lipopolyplex formulations analyzed with an agarose gel
shift assay (A) siRNA polyplexes formed with lipo-oligomers bearing no (T-0N3), one (T-1N3) and
two (T-2N3) azide functions incubated with 0.75 equivalents of DBCO-pSar119 1% agarose gel, 70 V,
80 min runtime; (B) Formulations with increasing equivalents (eq mol/mol) of DBCO-pSar119. 0.75%
agarose gel, 100 V, 80 min runtime. Polyplexes were incubated for 40 min at N/P 12, followed by
DBCO-pSar119 addition for 16 h at room temperature. The right lane in each gel shows the running
distance of free siRNA not complexed by lipo-oligomers.
A second indirect measure for the efficiency of polyplex shielding is the zeta potential or
electrochemical mobility. The latter can be determined by measuring a particle’s mobility in an electric
field with light scattering.
In this respect, we observed that the positive zeta potential of an unshielded particle can be
strongly reduced from 21 mV to 6 mV in case of T-1N3 polyplexes and from 17 mV to 3 mV in
case of T-2N3 polyplexes, when the particle is shielded with an excess of DBCO-pSar119 (Table 1).
By using 0.5 eq DBCO-pSar119/oligomer, the zeta potential can already be reduced to 50%. It should
be noted here that due to the N-terminal cationic tail group, the zeta potential always remained
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slightly positive. As determined by single-angle dynamic light scattering (DLS), hydrodynamic
diameters of the polyplexes were approximately 100 nm. With increasing amounts of DBCO-pSar119,
the nanoparticle size increased by up to 16 nm in diameter. The most plausible explanation for the
increase in size seems to be pSar covering the particle surface.
Table 1. Particle size (z-average) and zeta potential of pSar-shielded siRNA formulations determined
by a dynamic light scattering (DLS) zetasizer. siRNA polyplexes were prepared at N/P 12.
siRNA
Formulation
eq
DBCO-pSar119
z-Average
(nm) PDI
Mean Zeta
Potential (mV)
T-1N3
0 81.0 ± 5.0 0.26 ± 0.02 20.9 ± 0.9
0.5 86.7 ± 2.8 0.24 ± 0.02 9.4 ± 0.5
1 91.8 ± 2.9 0.26 ± 0.02 8.5 ± 0.6
2 96.8 ± 4.0 0.27 ± 0.02 6.0 ± 1.1
T-2N3
0 90.6 ± 0.9 0.15 ± 0.03 17.2 ± 0.8
0.5 98.7 ± 1.3 0.15 ± 0.01 7.7 ± 0.6
1 102.3 ± 2.1 0.19 ± 0.01 6.3 ± 1.0
2 105.1 ± 1.9 0.17 ± 0.01 2.5 ± 0.3
3.4. Evaluation of pSar-Shielding Agents In Vitro
Through the incorporation of pSar the unspecific interaction of polyplexes with cell membranes
should be efficiently reduced as already demonstrated for other stealth-like polymers, e.g., PEG.
To prove our assumption we performed uptake studies with pSar-shielded polyplexes. Formulations
were prepared with Cy5-labled siRNA for this assay to follow the fluorescent cargo, incubated with
neuroblastoma Neuro2a cells for 4 h at standard culture conditions and analyzed by flow cytometry.
The signal intensity of cells bearing fluorescent dyes correlates with the amount of polyplexes being
internalized (Table 2 and Figure S3). Unshielded material and material shielded with low equivalents
of DBCO-pSar119 showed significant uptake into cells already after 4 h incubation time for polyplex
formulations prepared with one or two azide-bearing backbones (T-1N3 and T-2N3). For T-1N3
formulations, a significant reduction in fluorescence intensity of more than 50% was observed for 1 eq
of DBCO-pSar119 per oligomer, whereas 2 eq of DBCO-pSar119 were needed for T-2N3 formulations
to reduce cell uptake (Table 2).
Table 2. Mean fluorescence intensity (MFI) of Cy5-labeled siRNA formulations (top: T-1N3; bottom:
T-2N3) shielded with increasing equivalents (eq mol/mol) of DBCO-pSar119 for cellular internalization
determined by flow cytometry.
siRNA
Formulation
eq
DBCO-pSar119
MFI
T-1N3
0 881.5 ± 25.5
0.25 780.5 ± 2.5
0.5 715.0 ± 24.0
1 359.0 ± 14.0
2 245.5 ± 8.0
T-2N3
0 883.0 ± 86.0
0.25 870.5 ± 62.5
0.5 785.5 ± 38.5
1 602.5 ± 37.5
2 263.5 ± 4.5
untreated cells 2.4 ± 0.2
The effect on internalization can be visualized by confocal laser scanning microscopy (CLSM).
Cells were incubated with T-1N3 siRNA formulations for 4 h and the Cy5-labeled siRNA (red)
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representing the localization of the polyplex was detected (Figure 3). Compared to the unshielded
material that was avidly taken up by cells, 0.5 eq of DBCO-pSar119 showed a slight reduction in
cellular internalization. For 1 eq of DBCO-pSar119, only a few polyplexes were taken up by cells,
indicating efficient shielding ability. This experiment reconfirmed the observations already made in
the flow cytometry studies.
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Figure 3. Intracellular distribution of T-1N3 siRNA formulations in Neuro2a-eGFP-Luc cells with
increasing equivalents (eq mol/mol) of DBCO-pSar119 acquired with a confocal laser scanning
microscop. Cells were incubated with the formulations for 4 h and washed with PBS buffer. siRNA
was spiked with 20% Cy5-labeled siRNA (red), nuclei were stained with DAPI (blue). The overlay
image shows the light microscope image and the merged DAPI and Cy5 channels. Scale bar: 10 µm.
In conclusion, covalent surface modification of polyplexes by SPAAC reduced cell binding and
uptake substantially. Interestingly, the increase of azide functionalities in the T-2N3 backbone did not
lead to a better surface passivation of the formed polyplex. As depicted in Table 2, both polyplexes
behave comparably and differ only slightly at full polysarcosinylation levels. This observation may
relate to differences in microstructure between T-1N3 and T-2N3 based polyplexes, which seem to
influence the accessibility of azide on the polyplex surface.
3.5. Distribution of pSar-Functionalized Polyple es In Vivo
After the shielding ability of pSar-functionalized polyplexes could be demonstrated in biophysical
and in vitro assays, we aim to explore the in vivo behavior of polysarcosinylated polyplexes.
For in vivo biodistribution studies, the unshielded T-1N3 siRNA polyplex, which showed the
lowest interaction with cells, was used to prepare a formulation to which either DBCO-PEG5k and
a formulation using acetylated polysarcosine (DBCO-pSar119-Ac; Figure 1, bottom) was covalently
linked by SPAAC. The acetyl end group of DBCO-pSar119-Ac seems to be better comparable to the
commercial methoxylated PEG agent in terms of surface polarity. The cap of the N-terminal sarcosine
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slightly reduced migration distance of polyplexes in the gel in comparison to the non-acetylated pSar
(Table S2, Figure S4). T-1N3 siRNA polyplexes were prepared with 50% Cy7-labeled siRNA followed
by 4 h incubation with 1 eq of the respective shielding agent per oligomer. The final concentration of
siRNA in the formulation was 200 ng/µL in this experiment. 50 µg of siRNA and oligomers at an N/P
ratio of 10 were used.
The formulations were administered to Neuro2a tumor-bearing mice via tail-vain injection and the
distribution of the near infrared (NIR) fluorescent dye attached to the siRNA was monitored at various
time points over 24 h by bioimaging in mice (Figure 4 and Figure S5). The unshielded polyplexes
started accumulating in the liver after 15 min. Such a finding could also be observed for other
unshielded siRNA formulations with cationic T-shape structures in previous work [89,90]. In contrast
to the unshielded polyplexes, both shielded formulations showed much-extended circulation times
and tumor accumulation. 60 min after i.v. injection of the material, the shielded formulations were
still detectable in all parts of the body including the tumor site. The intensity of the signals decreased
after 4 h, indicating a slow removal of polyplexes from circulation. The strongest signals remained
in liver and bladder, which indicates that the stability of polyplexes coated with PEG or pSar is
enhanced but not infinite and the labeled siRNA can leave the polyplex ending up in liver and
kidney. To further enhance stability bioreversible core cross-linking is required [79,80,97]. In mice
injected with shielded polyplexes, a strong signal was detected in the exposed periphery, such as the
paws after more than 4 h (Figure S5). In direct comparison, polyplexes with the DBCO-pSar119-Ac
and the DBCO-PEG5k displayed negligible differences in biodistribution, circulation time or tumor
accumulation. A pronounced accumulation at the tumor site, however, could not be observed and
may require further strategies to enhance tumor accessibility and retention.
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Figure 4. Biodistribution of T-1N3 siRNA formulations (50 µg siRNA; 50% Cy7-labeled) in NMRI-nude
mice bearing Neuro2a tumors after i.v. administration. NIR fluorescence bioimages show formulations
with 1 eq DBCO-PEG5k, 1 eq acetylated DBCO-pSar119-Ac or HBG buffer (non-shielded). Experiments
were performed with two mice per group for time points until 60 min and one mouse per group for
later time points; a representative mouse of each group is shown. Mice are presented in the dorsal,
ventral and lateral view.
3.6. Attachment of the Targeting Ligand Folate to Polysarcosine
The inhibition of unspecific cell association is an important requirement for any specific interaction
with cell surface receptors or proteins in solution. Thus, attaching a targeting ligand onto shielded
polyplexes is expected to enable targeting of specific cell surface receptors. Since pSar can be further
functionalized at its free secondary amino function, we chose folic acid (FolA) as a ligand to be
conjugated to the N-terminus of DBCO-pSar110 by peptide bond formation. Folic acid is an interesting
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ligand, because it is a commercially available small molecule with carboxyl groups for conjugation
and it is the natural ligand to the folic acid receptor (FR) overexpressed on several tumor types, e.g.,
prostate cancer [82–84,98–101]. The applied coupling conditions using equimolar amounts of folic acid,
DBCO-pSar polymer and coupling reagents (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBt)) and the steric hindrance of the polymer
avoid the formation of divalent folic acid conjugates. Concerning regioselectivity, it has been reported
that both isoforms result for N,N-dicyclohexylcarbodiimide (DCC)-mediated amidation in DMSO or
DMSO/DMF, but with an observed regioselectivity of 80% for the γ-conjugate (DBCO-pSar110-FolA;
Figures 1 and 5, Table S1) [102].
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Figure 5. Characterization of DBCO-pSar ligands for post-shielding of polyplexes. (A) GPC elugrams of
DBCO-pSar in HFIP with different end groups; (B) UV-vis spectrum of DBCO-pSar and DBCO-pSar-FolA,
respectively; (C) 1H-NMR spectrum of DBCO-pSar-FolA in DMSO-d6 (400 MHz).
The properties of T-1N3 siRNA polyplexes equipped with this negatively charged ligand changed
in an unexpected way. For increasing equivalents, aggregates with high polydispersity were found
by DLS (Table S1). An interesting observation was the change in size from around 80 to 25 nm of
nanoparticles when folic acid was involved, which indicates strong compactation of the polyion
complex. For small degrees of particle surface modification with DBCO-pSar110-FolA, the size of
polyplexes only changed marginal compared to unshielded polyplexes.
For higher equivalents, aggregates were found in DLS measurements. Similar findings were
observed for folic acid-targeted lipopolyplexes before [103]. In the latter case, aggregation could be
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prevented by incorporation of tetra-glutamylated folic acid into the agent. We observed that for further
increase ofDBCO-pSar110-FolA to equimolar ratios, small defined particles of ~25 nm were found. This
can be explained with DBCO-pSar110-FolA-induced instability following a complete rearrangement of
particles to a uniform population. The folic acid’s chemical properties—its hydrophobic character and
negative charge—seem to play a major role in this reassembly process, because it was not observed for
untargeted polysarcosine-shielded particles. We need to state clearly that currently the effect of FolA
on polyplex formation is not understood and requires more detailed physicochemical studies.
When testing the folate targeted formulation with DBCO-pSar110-FolA on a FR-overexpressing
KB/eGFPLuc cell line, we found that targeted polyplexes showed increased binding to the cell surface,
which could be blocked by folic acid competition (Figure S6A) ensuring FR mediated binding. Much
to our surprise, the internalization of the polyplexes into the cell was extremely low (Figure S6A,B).
As a consequence, no gene silencing activity was achieved with such systems (Figure S6C). Limitations
in endosomal escape, often reported as being responsible for bad transfection efficiencies [104–108],
can be excluded, since co-incubation with the lysosomotropic agent chloroquine did not improve
gene silencing activity (Figure S6D). The trafficking of the vitamin folate via FR is reported to occur
by a non-caveolar, non-clathrin pathway also known as CLIC/GEEC endocytosis pathway [105,109].
For folate-targeted nanoparticles however, it could be demonstrated that pathways like caveolae- and
clathrin-mediated endocytosis occur [106–108]. The size and the ligand density on the particle surface
were reported to influence the cellular uptake pathway. The well shielded, ~25 nm siRNA polyplexes do
not seem to trigger any of the pathways in HeLa-derived KB cells efficiently. Further, the bioreducible
carrier T-1N3 within the liopolyplex might be an easy prey for disulfide cleavage, which was reported
to occur distinctly in the extracellular environment of HeLa cells [110]. The consequence of insufficient
cellular uptake was a lack of gene silencing activity. This effect has been observed for folate-targeted
polyplexes with 3.5 kDa PEG chains before [86]. At this point, we cannot provide an explanation for
the observed findings and further studies need to be conducted to understand the fact that specific
receptor binding was achieved, while receptor mediated endocytosis seems to be inhibited. In light of
these in vitro data, a transfer of targeted polyplexes to in vivo studies was not performed based on
ethical considerations.
4. Conclusions
To investigate the use of ability of pSar to shield polyplexes and enhance their circulation times
and reduce unspecific interactions, we synthesized a polyplex formulation based on sequence defined
lipo-oligomers and applied PEG and pSar based polymers for shielding of the preformed polyplexes.
In previous work, a novel class of redox-sensitive lipo-oligomers for siRNA delivery was successfully
established [39]. One of the best performing candidates from this work was chosen and extended by
a click-reactive azide functionality, resulting in carrier T-1N3. After the formation of siRNA polyplexes,
the particle surface was functionalized with the shielding agent polysarcosine. The SPAAC could
be performed between the DBCO-pSar polymer and the azide-containing lipo-oligomers within the
polyplex. In addition, it was demonstrated that the grafting could be controlled stoichiometrically
introducing a shielding layer. The shielding of the formed pSar corona has been observed in vitro in
gel retardation assays and cell studies. In contrast to unmodified polyplexes, binding and cellular
uptake was substantially reduced for all pSar-modified systems.
Furthermore, biodistribution in mice revealed that 8 kDa polysarcosine can clearly expand the
circulation of the siRNA lipopolyplexes from several minutes to hours. The difference in non-shielded
and shielded formulations is most pronounced at the 60 min time point, where in case of non-shielded
polyplexes, most of the polyplexes have accumulated in the liver, but stable circulation is still observed
for pSar-shielded polyplexes. While the biodistribution between non-modified polyplexes and
polysarcosinylated systems differ substantially, such systems behaved similar to PEGylated polyplexes
in vivo. Therefore, we can conclude that in terms of polyplex shielding, pSar and PEG behave
identically and can be both applied to reduce unspecific interactions of lipo-oligomer polyplexes and
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thus enhance blood circulation substantially from minutes to hours. When DBCO-pSar was, however,
modified with folic acid to target cell surface receptors, not only the size of polyplexes was reduced
from 80 to 25 nm, but also specific binding to FR-positive KB cell membranes did not boost cellular
internalization. Therefore, we need to conclude that further investigations are necessary to combine
favorable in vivo shielding with efficient receptor-targeted gene silencing for pSar-functionalized
lipo-oligomer polyplexes.
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heterotelechelic DBCO-pSar ligands, Table S2: Particle size and zeta potential of siRNA formulations determined
with a DLS zetasizer.
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